NCT05083039 is a clinical trial in Coronavirus Infections, sponsored by Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products.

What condition does NCT05083039 study?

NCT05083039 studies Coronavirus Infections, Vaccine, Polio.

Is NCT05083039 still recruiting?

NCT05083039 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT05083039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19

Completed Last updated 8 February 2023

What this trial tests

trial in Coronavirus Infections in 1,500 participants. Completed in 3 September 2021.

Timeline

14 May 2020

Primary endpoint
14 December 2020

3 September 2021

Quick facts

Lead sponsor	Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	14 May 2020
Primary completion	14 December 2020
Estimated completion	3 September 2021
Sites	1 location across Russia

Conditions studied

Coronavirus Infections — all drugs for Coronavirus Infections →
Vaccine — all drugs for Vaccine →
Polio — all drugs for Polio →

Sponsor

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products — full company profile →

Who can join

Adults 18 to 65, any sex, with Coronavirus Infections or Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence.
Yagovkina NV, Zheleznov LM, Subbotina KA, Tsaan AA, et al · · 2022 · cited 25× · PMID 35711442 · DOI 10.3389/fimmu.2022.907341

Verify or expand the search:

Other recruiting trials for Coronavirus Infections

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT05276388 — Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19) · active not recruiting
NCT04429594 — Study of the Incidence of SARS-CoV-2 Infection (COVID-19) · NA · recruiting
NCT04327570 — In-depth Immunological Investigation of COVID-19. · recruiting
NCT04318366 — COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor · recruiting

Other Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products trials

Trials by the same sponsor.

NCT05715918 — Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whol · Phase 3 · unknown
NCT05407142 — An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of th · Phase 3 · unknown
NCT05765773 — An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (C · Phase 2 · completed
NCT05046548 — This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inacti · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05083039 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05083039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing